Compared to patients with estrogen receptor-negative (ER-, ER<1% is considered ER-) breast cancer, patients with estrogen receptor-positive (ER+, ER>=1% is considered ER+) breast cancer had a better prognosis (8). This evidence concerns the gene ESR1 and breast carcinoma.